Abstract
The objective of this study is to compare risk adjusted matched cohorts of Charcot
neuroarthropathy patients who underwent osseous reconstruction with and without diabetes.
The 2 groups were matched based on age, body mass index, hypertension, history of
end-stage renal disease, and peripheral arterial disease. Bivariate analysis was performed
for preoperative infection, location of Charcot breakdown, and post reconstruction
outcomes, in patients with a minimum of 1 year follow-up period. Through bivariate
analysis, presence of preoperative ulceration (p = .0499) was found to be statistically more likely in the patients with diabetes;
whereas, delayed osseous union (p = .0050) and return to ambulation (p ≤ .0001) was statistically more likely in patients without diabetes. The nondiabetic
Charcot patients were 17.6 folds more likely to return to ambulation (odds ratio [OR]
17.6 [95% confidence interval {CI} {3.5-87.6}]), and 16.4 folds more likely to have
delayed union (OR 16.4 [95% CI {1.9-139.6)]). Subanalysis compared well-controlled
diabetic and nondiabetic Charcot neuroarthropathy patients for same factors. Multivariate
analysis, in the subanalysis, found return to ambulation was 15.1 times likely to
occur in the nondiabetic CN cohort (OR 15.1 [95% CI 1.3-175.8]) compared to the well-controlled
diabetic CN cohort.
Level of Clinical Evidence
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of Foot and Ankle SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Charcot neuro-osteoarthropathy.Diabetes/Metabolism Res Rev. 2008; 24: S62-S65
- The pathogenesis of Charcot neuroarthropathy: current concepts.Diabetic Foot Ankle. 2012; 3: 1-4
- The Charcot joint: a modern neurologic perspective.J Clin Neuromusc Dis. 2011; 13: 1-13
- The diabetic Charcot foot.Israel Med Assoc J. 2004; 6: 280-283
- Neuroarthropathy in diabetes: pathogenesis of Charcot arthropathy.Bone Joint Res. 2018; 7: 373-378
- The Charcot foot in diabetes.Diabetes Care. 2011; 34: 2123-2129
- An overview of the Charcot foot pathophysiology.Diabetic Foot Ankle. 2013; 4: 1-9
- Charcot neuroarthropathy in patients with diabetes: an updated systematic review of surgical management.J Foot Ankle Surg. 2016; 55: 586-590
- Alcohol-induced neuroarthropathy in the foot: a case series and review of literature.J Foot Ankle Surg. 2008; 47: 118-124
- Charcot arthropathy of the foot and ankle.Foot Ankle Int. 2016; 37: 1255-1263
- Charcot foot associated with chronic alcohol abuse.BMJ Case Rep. 2013;
- Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2014; 32: 1941-1967
- Epidemiology of the Charcot foot.Clin Podiatr Med Surg. 2008; 25: 17-28
- Charcot spine as a late complication of traumatic spinal cord injury.Arch Phys Med Rehabilit. 1997; 78: 221-225
- Central post-stroke pain: clinical characteristics, pathophysiology, and management.Lancet. 2009; 8: 857-868
- Charcot arthropathy of the foot and ankle in patients with idiopathic neuropathy.Foot Ankle Int. 2014; 35: 996-1001
- Pedal neuroarthropathy in a nondiabetic patient as a result of long-term amiodarone use.J Foot Ankle Surg. 2009; 48: 362-364
- HIV neuropathy induced Charcot neuroarthropathy: a case discussion.Foot. 2012; 22: 112-116
- Vincristine-induced neuroarthropathy (Charcot's joint).J Am Podiatr Med Assoc. 2000; 90: 478-480
- Severe Sensory Neuronopathy in primary Sjögren syndrome resulting in Charcot arthropathy.J Rheumatol. 2016; 43: 1449-1451
- Risk factors of diabetic foot Charcot arthropathy: a case-control study at a Malaysian tertiary care center.Singapore Med J. 2016; 57: 198-203
- Budiman-Mak E. Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer.Diabetes Care. 2009; 33: 98-100
- Comparison of diabetic Charcot patients with and without foot wounds.Foot Ankle Int. 2017; 38: 140-148
- Diabetic foot biomechanics and gait dysfunction.J Diabetes Sci Technol. 2010; 4: 833-845
- Human Achilles tendon glycation and function in diabetes.J Appl Physiol. 2016; 120: 130-137
- Intrinsic muscle atrophy and toe deformity in the diabetic neuropathic foot: a magnetic resonance imaging study.Diabetes Care. 2002; 25: 1444-1450
- Ankle equinus deformity and Its relationship to high plantar pressure in a large population with diabetes mellitus.J Am Podiatr Med Assoc. 2002; 92: 479-482
- Surgical decision making in hammertoe deformity.in: Vickers NS Reconstructive Surgery of the Foot and Leg: Updated in Tucker GA Podiatry Institute. 1997
- Lesser ray deformities.McGlamry's Comprehensive Textbook of Foot and Ankle Surgery. ed 3. Lippincott Williams & Wilkins: Wolters Kluwer, Philadelphia2001
- Amputation and ambulation in diabetic patients: function is the goal.Diabetes/Metabolism Res Rev. 2012; 28: 93-96
- Investigation of standing balance in patients with diabetic neuropathy at different stages of foot complications.Clin Biomech. 2008; 23: 1183-1191
- Glucocorticoid-induced osteoporosis: pathophysiology and therapy.Osteoporosis Int. 2007; 18: 1319-1328
- Glucocorticoid-induced bone disease.New Engl J Med. 2011; 365: 62-70
- Charcot neuroarthropathy after simultaneous pancreas-kidney transplant.Transplantation. 2012; 94: 642-645
- Antiinflammatory action of glucocorticoids—new mechanisms for old drugs.New Engl J Med. 2005; 353: 1711-1723
- Glucocorticoid-induced osteoporosis.in: Marcus R Osteoporosis. ed 3. Elsevier-Academic Press, San Diego2008
- Bone mineral density in people living with HIV: a narrative review of the literature.AIDS Res Ther. 2017; 14: 35
- The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis.Osteoporosis Int. 2017; 29: 287-303
- Cancer treatment-induced bone loss in breast and prostate cancer.J Clin Oncol. 2008; 26: 5465-5476
- Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals.J Infect Dis. 2016; 214: 607-611
- Skeletal response to alcohol.Alcoholism. 2000; 24: 1693-1701
- Acute alcohol exposure impairs fracture healing and deregulates β‐catenin signaling in the fracture callus.Alcoholism. 2012; 36: 2095-2103
- Risk factors contributing to fracture non-unions.Injury. 2006; 38: 11-S18
- Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.AIDS. 2006; 20: 2165-2174
- Osteoporosis after stroke: a review of the causes and potential treatments.Cerebrovasc Dis. 2009; 28: 191-200
- Metformin alleviates hyperglycemia-induced apoptosis and differentiation suppression in osteoblasts through inhibiting the TLR4 signaling pathway.Life Sci. 2019; 216: 29-38
- Metformin decreases reactive oxygen species, enhances osteogenic properties of adipose-derived multipotent mesenchymal stem cells in vitro, and increases bone density in vivo.Oxidative Med Cell Longevity. 2016; 2016: 1-19
- Principles of bone healing.J Neurosurg. 2001; 10: 1-4
Article info
Publication history
Published online: August 07, 2020
Footnotes
Financial Disclosure: None reported.
Identification
Copyright
© 2020 by the American College of Foot and Ankle Surgeons. All rights reserved.
